Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin

Inclusion Criteria: * Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. * Subjects must be \>=35 years and \<=70 years of age. * Subjects must have an LDL-C concentration \>=2.6 mmol/L and TC concentration \>=4.14 mmol/L * Body mass index (BMI) must be within the range of 19 to 30 for patients. * Subjects must have documented coronary heart disease with one or more of the following features: * Documented stable angina (with evidence of ischemia on exercise testing) * History of myocardial infarction * History of percutaneous coronary intervention (with or without stent placement) * Documented history of unstable angina or non-Q wave myocardial infarction. Exclusion Criteria: * Diabetes and endocrine or metabolic disease. * Congestive heart failure defined by New York Heart Association (NYHA) as Class III or IV. * Uncontrolled cardiac arrhythmia. * Uncontrolled hypertension (Systolic BP \>160 mm Hg and/or Diastolic BP \>100 mmHg on two consecutive measurements). * Liver or kidney disease confirmed by abnormal lab values or function. * Smokers who report cigarette use of more then 10 cigarette per day. * Subjects who consume \>2 alcoholic drinks a day. (A drink is: a can of beer, glass of wine, or single measure of spirits). * Known human immunodeficiency virus (HIV) positive. * Cancer. * Subjects who are on any of the following concomitant medications: * Medications that are potent inhibitors of CYP3A, including cyclosporine, itraconazole, fluconazole, and ketoconazole, erythromycin or clarithromycin, nefazodone, protease inhibitors,mibefradil and large amounts of grapefruit juice (\>1 quart/day). * Lipid-lowering agent: niacin (\>200 mg/day) taken within 5 weeks, fibric acid derivatives taken within 8 weeks.